Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2009-12-23
2011-11-22
Foley, Shanon A (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
08063031
ABSTRACT:
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
REFERENCES:
patent: 3914402 (1975-10-01), Shell
patent: 3986510 (1976-10-01), Higuchi et al.
patent: 4180646 (1979-12-01), Choi et al.
patent: 4853224 (1989-08-01), Wong
patent: 4863457 (1989-09-01), Lee
patent: 4997652 (1991-03-01), Wong
patent: 5164188 (1992-11-01), Wong
patent: 5378475 (1995-01-01), Smith et al.
patent: 5443505 (1995-08-01), Wong
patent: 5501856 (1996-03-01), Ohtori et al.
patent: 5660851 (1997-08-01), Domb
patent: 5766242 (1998-06-01), Wong
patent: 5773019 (1998-06-01), Ashton et al.
patent: 5824072 (1998-10-01), Wong
patent: 5869079 (1999-02-01), Wong
patent: 5902598 (1999-05-01), Chen et al.
patent: 6046187 (2000-04-01), Berde et al.
patent: 6063116 (2000-05-01), Kelleher
patent: 6074661 (2000-06-01), Olejnik et al.
patent: 6548078 (2003-04-01), Guo et al.
patent: 6726918 (2004-04-01), Wong et al.
patent: 7033605 (2006-04-01), Wong
patent: 0430539 (1990-11-01), None
patent: WO 99/11244 (1998-08-01), None
American Academy of Ophthalmology; Basic and Clinical Science Course: Intraocular inflammation and Uveitis Section 9, 2003-2004 57-80, 102-103, 152-156.
Apel et al.; A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy; Current Eye Research; 1995; 659-667.
Aguilar, H.E. et al, (1995). “Vancomycin Levels After Intravitreal Injection”, Retina 15: 428-432.
Araie, M. and Maurice, D.M. (1991). The Loss of Fluorescein, Fluorescein Glucoronide and Fluorescein Isothiocyanate Dextran From the Vitreous by the Anterior and Retinal Pathways >>, Exp. Eye. Res. 52, 27-39.
Barza, M. et al (1983). << Pharmacokinetics of Intravitreal Carbenicillin, Cefazolin, and Gentamicin in Rhesus Monkey >>, Invest. Ophthalmol. Vis. Sci. 24: 10602-1606.
Ben-Nun, J. et al, (1989). “Pharmacokinetics of Intravitreal Injection”, Investigative Ophthalmology & Visual Science 30(6): 1055-1061.
Bloch-Michel, Etienne; Opening Address: Intermediate Uveitis; Boke WRF, Manthey KF, Nussenblatt RB (eds):Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, vol. 23; 1-2.
Bodor et al.; A comparison of intraocular pressure elevation activity of loteprednol etabonate and dexamethasone in rabbits;Current Eye Research, 1992, 11, 525-30.
Boke WRF, Manthey KF, Nussenblatt RB (eds): Clinical Picture of Intermediate Uveitis;Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, vol. 23; 20-27.
Challa, J.K. et al (1998). << Exudative Macular Degeneration and Intravitreal Triamcinolone : 18 month follow-up >>, Australian and New Zealand Journal of Ophthalmology 26 : 277-281.
Cheng et al.; Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis;Investigative Ophthalmology&Visual Science; Feb. 1995, vol. 36, No. 2; 442-453.
De Jong et al.; New insights into the hydrolytic degradation of poly (lactic acid): participation of the alcohol terminum;Polymer42 (2001) 2795-2802.
Dohlman C. et al.,Treatment of corneal edema with a buried implant, Tr. Am. Acad. Opth. & Otol., Mar.-Apr. 1966, pp. 267-280.
Enyedi, Laura et al., An Intravitreal Device Providing Sustained Release of Cyclosporine and Dexamethasone, Current Eve Research (1995) pp. 549-557.
Friedrich, S. et al (1997). “Finite Element Modeling of Drug Distribution in the Vitreous Humor of the Rabbit Eye”, Annals of Biomedical Engineering 25: 303-314.
Gould et al.; Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer as a drug delivery system for 5-fluorouracil: a histopathological evaluation;Can J Ophthalmol, vol. 29, No. 4, 1994; 168-171.
Hainsworth, Dean P. et al., Sustained Release Intravitreal Dexamethasone, Journal of Ocular Pharmacology and Therapeutics, (1996) vol. 12, No. 1, pp. 57-63.
Hayes, Robert C. Jr., Adrenocorticotropic Hormone: Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones, Chapter 60 at p. 1447 ofGoodman and Gilman's: The pharmacological Basis of Therapeutics, Eighth Edition, Pergamon Press1990.
Hayreh, S.S. (1996). “Posterior Drainage of the IntracularFluid From the Vitreous”. Exp. Eye. Res. 5: 123-144.
Jaffe, G.J. et al (1999). “Safety, Efficacy, and Pharmacokinetics of an Intravitreal Fluocinolone Sustained Drug Delivered System”, Investigative Ophthalmology & Visual Science 40 (4): 5988, Abstract No. 5195.
Jay, W.M. et al (1987). “Intravitreal Cefiazidine in a Rabbit Model: Dose-and Time-Dependent Toxicity and Pharmacokinetic Analysis,”J. Ocular Pharmcology 3 (3): 257-262.
Johnson, F. and Maurice D.(1984). “A Simple Method of Measuring Aqueous Humor Flow With Intravitreal Fluoresceinated Dextrans”, Exp. Eye. Res. 39: 791-805.
Kane, A. et al (1981), “Intravitreal Injection of Gentamicin in Rabbits”, Invest. Ophthalmol. Vis. Sci. 20(5): 593-597.
Kimura, H. and Ogura, Y (2001), “Biodegradable Polymers for Ocular Drug Delivery”, Ophthalmologica 215: 143-155.
Kochinke, F. et al., Biodegradable Drug Delivery System for Uveitis Treatment, Investigative Ophthalmology & Visual Science, Feb. 15, 1996, vol. 37. No. 3, 186-B98.
Kralinger, M.T. et al (2001) “Slow Release of Acetylsalicyclic Acid by Intravitreal Silicone Oil”, Retina, The Journal of Retinal and Vitreous Diseases, 21 (5): 513-530.
Kwak et al.; Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection;Arch Ophthalmol, vol. 110, Feb. 1992, 259-266.
Laurent, U.B.G. and Fraser, J.R.E. (1983). “Turnover or Hyualuronate in the Aqueous Humor and Vitreous Body of the Rabbit”, Exp. Eye. Res. 36: 493-504.
Lee et al.; Drug delivery to the posterior segment; Chapter 25 ofPrinciples of vitreoretinal therapy, vol. 1, Part 1, 1989, 483-498.
Maurice, David M.; Micropharmaceutics of the Eye;Ocular Inflammation Ther., 1; 1983, 97-102.
Maurice, D.M. and Mishima, S. (1984) Chapter 2: Ocular Pharmacokinetics, Handbook of Experimental Pharmacology, vol. 69, M.L. Sears (eds), Springer-Verlag, pp. 19-116.
Maurice, D.M. (1957), “The Exchange of Sodium Between the Vitreous Body and the Blood and Aqueous Humor”, J. Physiol. 137: 110-125.
Maurice, D.M. (1987). “Flow of Water Between Aqueous and Vitreous Compartments in the Rabbit Eye”, Am. J. Physiol. 252 (Renal Fluid Electrolyte Physiol. 21): F104-F108.
Morita Y., et al.,Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid)implants, Biol. Pharm. Bull., Feb. 1998; 21(2): 188-90.
Moseley H. et al (1984) “Routes of Clearance of Radioactive Water From the Rabbit Vitreous”, British Journal of Ophthalmology 68: 145-151.
Nakamura O., et al.,Inhibition of neovascularization and tumor growth by dexamethasone, No To Shinkei, Jan. 1992;44(1):37-41.
Ogden et al. editors; Retina—Basic Science and Inherited Retinal Disease vol. 1, St. Louis; CV Mosby, (1989).
Ohtori, A. and Tojo, K. (1994) “In vivo/in vitro Correlation of Intravitreal Delivery of Drugs With the Help of Computer Simulation”, Biol. Pharm.Bull. 17 (2): 283-290.
Olsen et al.; Human Scleral Permeability—Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning;Investigative Ophthalmology&Visual Science; Aug. 1995, vol. 36, No. 9, 1893-1903.
Park et al.; A new preparation method for protein loaded poly (D,L-lactic-coglycolic acid) Microspheres and protein release mechanism study;Journal of Controlled Release; 55 (1998),
Hu Mae W. L.
Wong Vernon G.
Allergan Inc.
Condino Debra D.
Foley Shanon A
German Joel B.
Wollenberger Louis V.
LandOfFree
Implants and methods for treating inflammation-mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Implants and methods for treating inflammation-mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Implants and methods for treating inflammation-mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267108